FCPT broadens its reach with the recent acquisitions of both the Tires Plus property and the automotive service property.

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.

CELH's rapid growth and innovation challenge PEP's scale and stability as both target the booming functional beverage market.

LOS ANGELES--(BUSINESS WIRE)---- $IBTA--IBTA Investors Have Opportunity to Lead Ibotta, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Ibotta, Inc. ("Ibotta" or the "Company") (NYSE:IBTA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Jay McCanless sets the foundation for Lennar's (LEN) earnings after the close. Expectations for the report are low, though persistently high interest rates can pose a challenge to its outlook.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 16, 2025 (GLOBE NEWSWIRE) -- Reeflex Solutions Inc. (TSXV: RFX) (“Reeflex” or the “Company”) is pleased to announce that it has entered into a credit agreement with the Royal Bank of Canada (“RBC”) for credit facilities (the “Credit Facilities”) that will support the Company's continued growth and operational flexibility, including working capital requirements and potential expansion opportunities. The Credit Facilities consist of: (i) a revolving demand facility in the amount of $1 million bearing interest at the Royal Bank Prime Rate + 1.25%; …

Luxury accessories giant Tapestry Inc TPR is getting a clear growth split between its key brands, according to JPMorgan analyst Matthew R. Boss.

Shares of Circle Internet Financial (NYSE: CRCL) surged 18.6% on Monday, extending a sharp rally that has seen the stock jump more than fivefold from its initial public offering two weeks ago. Circle made its trading debut on the New York Stock Exchange on June 5 after pricing its IPO above range.

Intelligent Bio Solutions collaborates with SMARTOX to expand U.S. forensic reach, boosting its drug test tech and eyeing FDA clearance for growth.

INOD trades at a premium despite underperforming peers YTD, with margin pressure weighing on sentiment.

Caterpillar lifts its quarterly dividend by 7% to $1.51, marking 31 straight years of hikes despite recent revenue softness.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=153322&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 3D Systems Corporation ("3D Systems" or the "Company") (NYSE:DDD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Investors that are well-acquainted with artificial intelligence (AI) know that some stocks, Nvidia (NVDA) chief among them, are more associated with the “AI stock” label than others. So, it can be argued that separating the AI contenders from the pretenders is an exercise in stock-picking.

Ratcheting geopolitical tensions in the Middle East mid-June add another layer of risk in 2025. In a tumultuous year defined by ongoing volatility, uncertainty, and risks, actively managed strategies appear well-positioned.

Last week's economic signals were a mix of cautious optimism and renewed concern. While inflation saw a slight uptick in May, it still came in cooler than expected.

The yield on the 10-year note ended June 13, 2025 at 4.41%. Meanwhile, the 2-year note ended at 3.96% and the 30-year note ended at 4.90%.

Sarepta Therapeutics, Inc. plunged over 47% after a second ELEVIDYS-related patient death, raising serious safety concerns and leading to trial suspensions. Despite the negative headlines and slashed FY25 guidance, I see the current valuation as deeply oversold and think long-term investors are best positioned to add at current levels. ELEVIDYS revenue dipped sequentially but remains up 180% year-over-year, and overall product revenue grew 70%, in my opinion, reflecting underlying business strength.

Refining margins have improved in the second quarter following the closure of three refineries and unexpected downtime at several domestic refineries. VLO is positioned to maintain its industry leading cost per barrel metric despite an elevated maintenance schedule in Q2. Closure of the Benicia refinery is projected to only increase the company's lead over the industry.